A cytotoxic anti-IL-3Rα antibody targets key cells and cytokines implicated in systemic lupus erythematosus

JCI Insight

Volumn 1, Issue 6, 2016, Pages

  Oon, Shereen ^a,b,c   Huynh, Huy ^d   Tai, Tsin Yee ^d   Ng, Milica ^d   Monaghan, Katherine ^d   Biondo, Mark ^d   Vairo, Gino ^d   Maraskovsky, Eugene ^d   Nash, Andrew D ^d   Wicks, Ian P ^a,b,c   Wilson, Nicholas J ^d  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d CSL LIMITED   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85055608647     PISSN: None     EISSN: 23793708     Source Type: Journal    
DOI: 10.1172/jci.insight.86131     Document Type: Article

References (50)

1. Bernatsky S, et al. Mortality in systemic lupus erythematosus. Arthritis Rheum. 2006; 54(8):2550-2557.
2. Borchers AT, Keen CL, Shoenfeld Y, Gershwin ME. Surviving the butterfly and the wolf: mortality trends in systemic lupus erythematosus. Autoimmun Rev. 2004; 3(6):423-453.
3. Bennett L, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med. 2003; 197(6):711-723.
4. Bauer JW, et al. Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus. PLoS Med. 2006; 3(12):2274-2284.
5. Petri M, et al. Sifalimumab, a human anti-interferon-alpha monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study. Arthritis Rheum. 2013; 65(4):1011-1021.
6. McBride JM, et al. Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study. Arthritis Rheum. 2012; 64(11):3666-3676.
7. Kalunian K, et al. A phase II study of the efficacy and safety of rontalizumab (rhuMAb inteferon-α) in patients with systemic lupus erythematosus (ROSE). Ann Rheum Dis. 2016; 75(1):196-202.
8. Furie R, et al. Anifrolumab, an anti-interferon alpha receptor monoclonal antibody, in moderate to severe systemic lupus erythematosus (SLE). Arthritis Rheumatol. 2015; 67(suppl 10):3223.
9. Liu YJ. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol. 2005; 23:275-306.
10. Llanos C, Mackern-Oberti JP, Vega F, Jacobelli SH, Kalergis AM. Tolerogenic dendritic cells as a therapy for treating lupus. Clin Immunol. 2013; 148(2):237-245.
11. Banchereau J, Pascual V. Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity. 2006; 25(3):383-392.
12. Bave U, Magnusson M, Eloranta ML, Perers A, Alm GV, Ronnblom L. Fcγ RIIa is expressed on natural IFN-α-producing cells (plasmacytoid dendritic cells) and is required for the IFN-α production induced by apoptotic cells combined with lupus IgG. J Immunol. 2003; 171(6):3296-3302.
13. Boule MW, Broughton C, Mackay F, Akira S, Marshak-Rothstein A, Rifkin IR. Toll-like receptor 9-dependent and -independent dendritic cell activation by chromatin-immunoglobulin G complexes. J Exp Med. 2004; 199(12):1631-1640.
14. Honda K, et al. IRF-7 is the master regulator of type-I inteferon-dependent immune responses. Nature. 2005; 434(7034):772-777.
15. Means TK, Latz E, Hayashi F, Murali MR, Golenbock DT, Luster AD. Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J Clin Invest. 2005; 115(2):407-417.
16. Chan VS, Nie YJ, Shen N, Yan S, Mok MY, Lau CS. Distinct roles of myeloid and plasmacytoid dendritic cells in systemic lupus erythematosus. Autoimmun Rev. 2012; 11(12):890-897.
17. Sisirak V, et al. Genetic evidence for the role of plasmacytoid dendritic cells in systemic lupus erythematosus. J Exp Med. 2014; 211(10):1969-1976.
18. Rowland SL, et al. Early, transient depletion of plasmacytoid dendritic cells ameliorates autoimmunity in a lupus model. J Exp Med. 2014; 211(10):1977-1991.
19. Farkas L, Beiske K, Lund-Johansen F, Brandtzaeg P, Jahnsen F. Plasmactyoid dendritic cells (natural interferon-α/β-producing cells) accumulate in cutaneous lupus erythematous lesions. Am J Pathol. 2001; 159(1):237-243.
20. Cederblad B, Blomberg S, Vallin H, Perers A, Alm GV, Ronnblom L. Patients with systemic lupus erythematosus have reduced numbers of circulating natural interferon-α producing cells. J Autoimmun. 1998; 11(5):465-470.
21. Blomberg S, Eloranta ML, Magnusson M, Alm GV, Ronnblom L. Expression of the markers BDCA-2 and BDCA-4 and production of interferon-α by plasmacytoid dendritic cells in systemic lupus erythematosus. Arthritis Rheum. 2003; 48(9):2524-2532.
22. Jin O, et al. Systemic lupus erythematosus patients have increased number of circulating plasmacytoid dendritic cells, but decreased myeloid dendritic cells with deficient CD83 expression. Lupus. 2008; 17(7):654-662.
23. Miyashita A, et al. Proportion of lymphocytic inflammation with CD123 positive cells in lupus erythematous profundus predict a clinical response to treatment. Acta Derm Venereol. 2014; 94(5):563-567.
24. Lande R, et al. 2011. Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus. Sci Transl Med. 2011; 3(73):73ra19.
25. Dzionek A, et al. BDCA-2, a novel plasmacytoid dendritic cell-specific type II C-type lectin, mediates antigen capture and is a potent inhibitor of interferon α/β induction. J Exp Med. 2001; 194(12):1823-1834.
26. Pellerin A, et al. Anti-BDCA2 monoclonal antibody inhibits plasmacytoid dendritic cell activation through Fc-dependent and Fc-independent mechanisms. EMBO Mol Med. 2015; 7(4):464-476.
27. Zhan Y, et al. Bcl-2 antagonists kill plasmacytoid dendritic cells from lupus-prone mice and dampen interferon-alpha production. Arthritis Rheumatol. 2015; 67(3):797-808.
28. Olweus J, et al. Dendritic cell ontogeny: a human dendritic cell lineage of myeloid origin. Proc Natl Acad Sci U S A. 1997; 94(23):12551-12556.
29. Broughton SE, et al. Dual mechanism of interleukin-3 receptor blockade by an anti-cancer antibody. Cell Rep. 2014; 8(2):410-419.
30. Busfield SJ, et al. Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC. Leukemia. 2014; 28(3):2213-2221.
31. Charles N, Hardwick D, Daugas E, Illei GG, Rivera J. Basophils and the T helper 2 environment can promote the development of lupus nephritis. Nat Med. 2010; 16(6):701-707.
32. Grouard G, Rissoan M, Filgueira L, Durand I, Banchereau J, Liu YJ. The enigmatic plasmacytoid T cells develop into dendritic cells with interleukin (IL)-3 and CD40-ligand. J Exp Med. 1997; 185(6):1101-1111.
33. Kadowaki N, et al. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med. 2001; 194(6):863-869.
34. Jego G, Palucka AK, Blanck JP, Chalouni C, Pascual V, Banchereau J. Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity. 2003; 19(2):225-234.
35. Hervier B, et al. Phenotype and function of natural killer cells in systemic lupus erythematosus: excess interferon-gamma production in patients with active disease. Arthritis Rheum. 2011; 63(6):1698-1706.
36. Lin SC, Kuo CC, Tsao JT, Lin LJ. Profiling the expression of interleukin (IL)-28 and IL-28 receptor α in systemic lupus erythematosus patients. Eur J Clin Invest. 2012; 42(1):61-69.
37. Wu Q, Yang Q, Lourenco E, Sun H, Zhang Y. Interferon-lambda1 induces peripheral blood mononuclear cell-derived chemokines secretion in patients with systemic lupus erythematosus: its correlation with disease activity. Arthritis Res Ther. 2011; 13(3):R88.
38. Amezcua-Guerra LM, Ferrusquia-Toriz D, Castillo-Martinez D, Marquez-Velasco R, Chavez-Rueda AK, Bojalil R. Limited effectiveness for the therapeutic blockade of interferon α in systemic lupus erythematosus: a possible role for type III interferons. Rheumatology (Oxford). 2015; 54(2):203-205.
39. Davidson A, Diamond B. Activated basophils give lupus a booster shot. Nat Med. 2010; 16(6):635-636.
40. Voehringer D. Basophil modulation by cytokine instruction. Eur J Immunol. 2012; 42(10):2544-2550.
41. Fishman P, et al. Interleukin-3 immunoassay in systemic lupus erythematosus: preliminary data. Int Arch Allergy Immunol. 1993; 100(3):215-218.
42. Renner K, et al. IL-3 contributes to development of lupus nephritis in MRL/lpr mice. Kidney Int. 2015; 88(5):1088-1098.
43. Smith BD, et al. 120 first-in man, phase I study of CSL362 (anti-IL3Rα/anti-CD123 monoclonal antibody) in patients with CD123+ acute myeloid leukemia (AML) in CR at high risk for early relapse. Blood. 2014; 124(21):120.
44. Cao W. Pivotal functions of plasmacytoid dendritic cells in systemic autoimmune pathogenesis. J Clin Cell Immunol. 2014; 5(2):212-234.
45. Rodriguez-Carrio J, Lopez P, Suarez A. Type I IFNs as biomarkers in rheumatoid arthritis: towards disease profiling and personalized medicine. Clin Sci (Lond). 2015; 128(8):449-464.
46. Goldberg A, et al. Dose-escalation of human anti-interferon-alpha receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study. Arthritis Res Ther. 2014; 16(1):R57.
47. Bissonnette R, et al. A randomized, double-blind, placebo-controlled, phase I study of MEDI-545, an anti-interferon-alpha monoclonal antibody, in subjects with chronic psoriasis. J Am Acad Dermatol. 2010; 62(3):427-436.
48. American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria. The American College of Rheumatology response criteria for systemic lupus erythematosus clinical trials: measures of overall disease activity. Arthritis Rheum. 2004; 50(11):3418-3426.
49. Petri M, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012; 64(8):2677-2686.
50. Edgar R, Domrachev M, Lasha AE. Gene expression omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2002; 30(1):207-210.